Xq28 (MECP2) microdeletions are common in mutation-negative females with Rett syndrome and cause mild subtypes of the disease
© Iourov et al.; licensee BioMed Central Ltd. 2013
Received: 15 November 2013
Accepted: 19 November 2013
Published: 27 November 2013
Rett syndrome (RTT) is an X-linked neurodevelopmental disease affecting predominantly females caused by MECP2 mutations. Although RTT is classically considered a monogenic disease, a stable proportion of patients, who do not exhibit MECP2 sequence variations, does exist. Here, we have attempted at uncovering genetic causes underlying the disorder in mutation-negative cases by whole genome analysis using array comparative genomic hybridization (CGH) and a bioinformatic approach.
Using BAC and oligonucleotide array CGH, 39 patients from RTT Russian cohort (in total, 354 RTT patients), who did not bear intragenic MECP2 mutations, were studied. Among the individuals studied, 12 patients were those with classic RTT and 27 were those with atypical RTT. We have detected five 99.4 kb deletions in chromosome Xq28 affecting MECP2 associated with mild manifestations of classic RTT and five deletions encompassing MECP2 spanning 502.428 kb (three cases), 539.545 kb (one case) and 877.444 kb (one case) associated with mild atypical RTT. A case has demonstrated somatic mosaicism. Regardless of RTT type and deletion size, all the cases exhibited mild phenotypes.
Our data indicate for the first time that no fewer than 25% of RTT cases without detectable MECP2 mutations are caused by Xq28 microdeletions. Furthermore, Xq28 (MECP2) deletions are likely to cause mild subtypes of the disease, which can manifest as both classical and atypical RTT.
KeywordsArray CGH Autistic spectrum disorder Chromosome X Female MECP2 Rett syndrome Xq28 microdeletion
Rett syndrome (RTT // MIM 312750) is an X-linked neurodevelopmental disorder caused by MECP2 mutations that affects almost exclusively girls. Clinically, the disease presents with developmental regression accompanied by the loss of hand skills, mobility and speech. In addition, RTT is phenotypically characterized by stereotypic hand movements, respiratory abnormalities, scoliosis, growth deficits, hypotonia, microcephaly and seizures. Intragenic MECP2 mutations are the main cause of RTT. However, there does exist a proportion of RTT females (5-10%) without detectable MECP2 mutations [1–6]. To date, genetic causes in these RTT cases remain largely unknown.
Recently, it has been shown that Xq28 microdeletions can affect MECP2 leading to RTT-like phenotype [7, 8]. Since these submicroscopic genome variations were commonly detected in children with presumably idiopathic intellectual disability, autism, epilepsy and/or congenital anomalies , it is probable that submicroscopic Xq28 deletions are not rare and can be associated with RTT. In this context, one can suggest Xq28 deletions spanning the MECP2 gene to be a potential cause of the disease in affected females without mutations detectable by Sanger sequencing. Surprisingly, to the best our knowledge, there was no systematic whole genome analysis of MEPC2-mutation negative RTT patients. In the available literature, we have only found studies describing whole genome analysis of RTT females by array comparative genomic hybridization (CGH), which was performed for testing whether copy number variants (CNVs) are able to modulate the phenotype in mutation-positive RTT cases [9, 10]. Thus, we decided to share our data on the evaluation of MEPC2-mutation negative females from Russian RTT cohort addressed by BAC and oligonucleotide array CGH with bioinformatic analysis.
Clinical and molecular overview of Xq28 microdeletions detected in MECP2- mutaiton-negative RTT females
Additional clinical features
Multiple hematomas, teeth anomalies
Prenatal hypotrophy, facial dysmorphisms
Prenatal hypotrophy, facial dysmorphisms, clinodactyly, dentinogenesis imperfecta, cerebellar vermis hypoplasia, epidural cystic changes in the thoracic spine
Prenatal hypotrophy, facial dysmorphisms, verrucous patches on the trunk, patent foramen ovale
Prenatal hypotrophy, facial dysmorphisms
Hydronephrosis, polycystic kidney disease
Prenatal hypotrophy, facial dysmorphisms
An attempt at correlation between genotype and phenotype in reported cases and cases with MECP2 mutations has shown that Xq28 (MECP2) microdeletions are likely to cause specific subtypes of RTT, which are clinically milder than the phenotype resulted from intragenic MECP2 sequence variations. Deletions were featured by late regression age, intact ability to walk, mild dyspraxia of hand movements, and microcephaly absence. Although some cases fulfil both canonical and more recent diagnostic criteria for classic RTT [11, 16], we did observe that almost all the RTT symptoms (addressed by a scale developed specifically for the evaluation of RTT symptoms severity [8, 14, 15]) in cases of Xq28 deletions are comparably milder than those caused by intragenic MECP2 mutations. Additional clinical signs featuring this RTT subtype are low birth weight in ~2/3 of cases, malformations (vascular dorsal skin hemangiomatosis, verrucous patches resembling incontinentia pigmenti phenotype, cerebellar vermis hypoplasia, polycystic kidney disease, patent foramen ovale) and facial dysmorphisms.
RTT is a common monogenic cause of neurodevelopmental abnormalities in females [1–6]. Although it has been repeatedly noted that the phenotype of affected girls depends on the presence or absence of MECP2 mutation, the latter have not been ever considered as an exclusive criterion for RTT [11, 16, 17]. Apparently, non-striking phenotypic differences between a significant proportion of mutation-positive and mutation-negative cases  indicate that the same genetic defect causes the disease in mutation-negative cases. Currently, there have been reported several genomic abnormalities (i.e. 14q12 microdeletions) associated with RTT [5–7, 18, 19]. However, these genomic rearrangements are unlikely to cover all the mutation-negative RTT cases. Here, we report on the commonest cause of RTT in cases without detectable MECP2 mutations. To our knowledge, this is the first systematic report describing Xq28 genomic abnormities (Xq28 deletions affecting MECP2) in RTT.
Large intragenic MECP2 deletions have been consistently reported in the available literature [20–24]. Moreover, a RTT case was associated with a deletion detected by FISH . Nevertheless, the existence of Xq28 deletions causing RTT has long remained a matter of conjecture. It seems that the high mutation detection rate and clinical heterogeneity in mutation-negative cases has resulted in the lack of studies dedicated to whole genome analysis among RTT females without detectable MECP2 mutations. On the other hand, MECP2 loss modulates RTT phenotypes in mice [25, 26] suggesting that similar genomic abnormality might cause RTT in humans. Xq28 (MECP2) deletions found in RTT girls has confirmed this expectation. Furthermore, studying functional consequences of MECP2 mutations [27–29] evidences that MECP2 loss has functional implications in females.
As detected by array CGH and FISH, one deletion causing classic RTT was mosaic. Somatic mosaicism for a structural chromosome abnormality or CNVs is common in genomic disorders or single-gene disease [30, 31]. It is also detected in cohorts of individuals with autistic spectrum disorders (in its widest sense) including girls suffering from RTT [12, 18, 32–35]. This makes it attractive to analyze molecular and clinical aspects of Xq28 (MECP2) deletions in the light of increasing interest in biomedical studies of autism, especially considering the positive experience in modelling neurodevelopmental abnormalities according to data on RTT pathogenesis [36, 37]. To explain differences between cell proportions uncovered by array CGH and FISH (Figure 3), one can compare molecular cytogenetic techniques in context of detecting somatic mosaicism [38–40]. In this instance, we have concluded that FISH results are more accurate. Similarly, FISH questioned in some detail the size of the recurrent deletion causing classic RTT. Since oligonucleotide probes cover a part of MECP2 sequence whereas the deletion was detectable by FISH with a probe for MECP2, we have speculated that genomic loss within Xq28 is a bit larger than shown by the array CGH. Likewise, sequence variations specifically generating Xq28 subchromosomal rearrangements are co-localized with the breakpoints outside of MECP2 loci [41, 42]. So far, it appears to be also valid for reported deletions. To determine the intrinsic nature and causes of Xq28 (MECP2) deletions leading to classic RTT, further studies are indisputably required.
The specific replication patterns in RTT or type C (observed in about 90% of affected children in contrast to unaffected females [12, 43]) have been detected in females with Xq28 microdeletions. The type C replication pattern represents a disturbance in the sequence of replication in an inactive chromosome X apparently caused by MECP2 mutations [12, 15]. These data allowed speculations that RTT in mutation-negative females is likely to be associated with genetic defects affecting the MECP2 gene . Array CGH analysis of RTT girls, highlighting Xq28 (MECP2) deletion as a new cause of the disease, confirms this assumption.
Although RTT phenotype is characterized by recognizable patterns of malformation and distinct neurodevelopmental abnormalities, there does exist a clinical variability among females suffering from this severe disorder [3–6, 11, 14, 16, 17]. Xq28 deletions causing atypical RTT have shown to exhibit additional phenotypic features (Table 1). This can be easily explained, because all deletions have spanned significantly larger regions than the MECP2 locus, involving other Xq28 genes, as well (Figure 2). Conversely, Xq28 losses (MECP2 plus some additional genes) should naturally lead to the presence of phenotypic manifestations usually unseen in RTT. Interestingly, RTT females with large Xq28 deletions have demonstrated less severe disease manifestations as compared to their counterparts with intragenic MECP2 mutations of known functional consequences. This is likely to result from X chromosome inactivation skewing probably arisen from selective disadvantages of cells with an active deleted chromosome X. In the same way, MECP2 deletions causing classic RTT are likely to lead to less severe RTT manifestations through the skewed X chromosome inactivation patterns. Thus, epigenetic phenotype modulators determine the outcome of subchromosomal deletions involving MECP2. This has led us to the conclusion that, regardless of specific phenotypic appearance, the Xq28 deletion phenotype is not different enough from RTT due to intragenic MECP2 mutations to define it as an independent clinical entity or a microdeletion syndrome. Summarizing the clinical data on girls found to demonstrate Xq28 (MECP2) microdeletions, we have concluded that these genomic rearrangements cause at least two distinct RTT subtypes. The first subtype is caused by deletions spanning from 0.5 to 1 Mb and is characterized by less severe RTT manifestations as well as additional clinical signs. The second subtype is caused by deletions spanning about 100 kb leading to a loss of MECP2 per se and is simply a less severe classic RTT. Finally, both types can be arbitrarily designated as microdeletion RTT subtype.
To this end, it is to mention that submicroscopic genomic variations and CNVs are likely to be among the commonest causes of congenital malformations, idiopathic intellectual disability, autism, epilepsy, neuropsychiatric disorders [18, 36, 44]. Seemingly, these genome variations are likely to be important elements of pathogenetic cascades in complex disease mediating genetic-environmental interactions . The present study evidences that submicroscopic deletions or CNVs cause single-gene disorders in an appreciable proportion of cases.
Using two array CGH platforms (BAC and oligonucleotide array CGH) and FISH, the existence of Xq28 deletions causing RTT was shown. To date, such genomic deletions were not actually recognized as a cause of RTT, a disease considered to be almost exclusively monogenic. We show that Xq28 (MECP2) deletions are common in RTT girls without detectable MECP2 sequence variations by Sanger sequencing affecting no fewer than 25% of mutation-negative females. Therefore, the efficiency of molecular diagnosis can be significantly increased through applying whole genome scan to mutation-negative RTT cases. Our data evidence that there exist at least two types of Xq28 microdeletions affecting MECP2: small deletions spanning about 100 kb and larger deletions spanning >100 kb (0.5-1 Mb). The former is likely to cause mild classic RTT, whereas the latter seems to result in mild atypical RTT forms. Finally, we conclude that Xq28 (MECP2) deletions are common in mutation-negative RTT girls and cause mild subtypes of the disease.
Thirty nine MECP2-mutation-negative females were recruited for molecular cytogenetic analysis according to molecular genetic data from the Russian RTT cohort (354 patients). All the girls fulfill clinical criteria for RTT either classic or atypical form. The information about Russian RTT cohort was provided previously [8, 12, 14, 15] and is partially given in Figure 1. The DNA samples studied were isolated from peripheral blood leukocytes following standard techniques. Written informed consent was obtained from the patients’ parents. The research was approved by the ethical committee at the Mental Health Research Center (Russian Academy of Medical Sciences) and by Russian Rett Syndrome Association.
The performance and results (partially) of Sanger sequencing was previously described [14, 15, 46]. The lack of a sequence variation in MECP2 known to be associated with RTT or to have a functional consequence was a criterion for entry into the study.
BAC-array CGH was performed using customized Constitutional Chip®4.0 (Human BAC Array-System, Perkin Elmer, USA) as described earlier [7, 47]. The resolution of the BAC-array has been estimated as 0.3 Mb for scanning chromosome X.
Oligonucleotide array CGH was performed using NimbleGen 135 K whole genome tiling array (described in parts by Duker et al. ). The calculated functional resolution was estimated 10–20 kb (95% confidence). Sample and reference DNA was labeled using Cy3-dUTP and Cy5-dUTP, respectively, and hybridized according to the manufacturer’s protocols (NimbleGen Arrays User’s Guide CGH and CGH/LOH Arrays v9.1, Roche NimbleGen, Madison, WI, USA). Scanning and image acquisition has been processed in the same way as for BAC-Perkin Elmer Array [7, 47].
FISH (probe labeling, hybridization and detection) was performed according to previously described protocols [12, 13, 35, 49]. The DNA probe was a YAC (yeast artificial chromosome) containing almost exactly MECP2 sequence and was kindly provided by Dr. Maurizio D’Esposito (Naples, Italy). The probe (localization and DNA sequence) was described previously .
Cytogenetic/cytological analysis of epigenetic phenomena
Unusual replication pattern or type C (detectable in nearly 90% of RTT children and unobserved in females without RTT [12, 43, 49]) i.e. disturbances in the replication sequence of an inactive chromosome X, was assessed by replication staining of metaphase chromosomes obtained from cultivated peripheral blood lymphocytes in the presence of 5-bromo-20-deoxyuridine as described in detail earlier [12, 43]. The presence of type C was evaluated by analyzing 50–100 metaphase plates.
Data analysis (bioinformatics)
The raw array CGH data (log 2 intensity ratios) were processed for CNV detection as proposed earlier [51, 52]. The protocol was modified to achieve comprehensive data on CNVs according to intensity ratios values for 4 oligonucleotide and 2 interchangeable BAC probes. Using different threshold schemes and background correction, the intensity ratios corresponding to CNVs spanning MECP2 were established empirically. Localization of probes in the oligonucleotide array CGH assay corresponding to MECP2 sequence was as follows: 153,299,881; 153,306,195; 153,308,602; 153,312,854. In BAC array CGH assay, there were 3 BAC probes for the X chromosome sequence encompassing the MECP2 gene. It is to note, that deletions have spanned larger regions than those covered by the probes strictly corresponding to MECP2 loci. The established threshold allowed the detection of non-mosaic and mosaic CNVs through the comparison of mean values of chromosome-specific intensity ratios and mean values of a locus of interest in Xq28.
Ivan Y Iourov and Svetlana G Vorsanova are joint first authors.
Copy number variations
Comparative genomic hybridization
Fluorescence in situ hybridization
Gene encoding methyl-CpG binding protein 2
Yeast artificial chromosome.
We would like to express our deepest gratitude to Olga V. Timutsa from the Russian Rett Syndrome Association for continuous support and kind assistance. We also thank children who took part in our study and their parents. Dr. M. D’Esposito (Naples, Italy) is acknowledged for providing MECP2- specific FISH probe. The study was supported by the Russian Rett Syndrome Association and by the Grant of the President of the Russian Federation MD-4401.2013.7.
Presented in part at the European Human Genetics Conference 2012, Nürnberg, Germany, June 23–26, 2012.
- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999, 23: 185–188. 10.1038/13810View ArticlePubMed
- Dragich J, Houwink-Manville I, Schanen C: Rett syndrome: a surprising result of mutation in MECP2. Hum Mol Genet 2000, 9: 2365–2375. 10.1093/hmg/9.16.2365View ArticlePubMed
- Vorsanova SG, Iourov IY, Yurov YB: Neurological, genetic and epigenetic features of Rett syndrome. J Pediatr Neurol 2004, 2: 179–190.View Article
- Weaving LS, Ellaway CJ, Gécz J, Christodoulou J: Rett syndrome: clinical review and genetic update. J Med Genet 2005, 42: 1–7. 10.1136/jmg.2004.027730PubMed CentralView ArticlePubMed
- Chahrour M, Zoghbi HY: The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56: 422–437. 10.1016/j.neuron.2007.10.001View ArticlePubMed
- Matsuishi T, Yamashita Y, Takahashi T, Nagamitsu S: Rett syndrome: the state of clinical and basic research, and future perspectives. Brain Dev 2011, 33: 627–631. 10.1016/j.braindev.2010.12.007View ArticlePubMed
- Iourov IY, Vorsanova SG, Kurinnaia OS, Zelenova MA, Silvanovich AP, Yurov YB: Molecular karyotyping by array CGH in a Russian cohort of children with intellectual disability, autism, epilepsy and congenital anomalies. Mol Cytogenet 2012, 5: 46. 10.1186/1755-8166-5-46PubMed CentralView ArticlePubMed
- Vorsanova SG, Iurov II, Voinova VI, Kurinnaia OS, Zelenova MA, Demidova IA, Ulas EV, Voinova VI, Iurov IB: Subchromosomal microdeletion identified by molecular karyotyping using DNA microarrays (array CGH) in Rett syndrome girls negative for MECP2 gene mutations. Zh Nevrol Psikhiatr Im S S Korsakova 2013, 113(10):47–52.
- Artuso R, Papa FT, Grillo E, Mucciolo M, Yasui DH, Dunaway KW, Disciglio V, Mencarelli MA, Pollazzon M, Zappella M, Hayek G, Mari F, Renieri A, Lasalle JM, Ariani F: Investigation of modifier genes within copy number variations in Rett syndrome. J Hum Genet 2011, 56: 508–515. 10.1038/jhg.2011.50PubMed CentralView ArticlePubMed
- Grillo E, Lo Rizzo C, Bianciardi L, Bizzarri V, Baldassarri M, Spiga O, Furini S, De Felice C, Signorini C, Leoncini S, Pecorelli A, Ciccoli L, Mencarelli MA, Hayek J, Meloni I, Ariani F, Mari F, Renieri A: Revealing the complexity of a monogenic disease: Rett syndrome exome sequencing. PLoS One 2013., 8: e56599
- Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, Leonard H, Bailey ME, Schanen NC, Zappella M, Renieri A, Huppke P, Percy AK: RettSearch Consortium: Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010, 68: 944–950. 10.1002/ana.22124PubMed CentralView ArticlePubMed
- Vorsanova SG, Yurov YB, Ulas VY, Demidova IA, Sharonin VO, Kolotii AD, Gorbatchevskaia NL, Beresheva AK, Soloviev IV: Cytogenetic and molecular-cytogenetic studies of Rett syndrome (RTT): a retrospective analysis of a Russian cohort of RTT patients (the investigation of 57 girls and three boys). Brain Dev 2001, 23(Suppl 1):S196-S201.View ArticlePubMed
- Yurov YB, Vorsanova SG, Kolotii AD, Iourov IY: Molecular-cytogenetic investigation of skewed chromosome X inactivation in Rett syndrome. Brain Dev 2001, 23(Suppl 1):S214-S217.View ArticlePubMed
- Vorsanova SG, Ulas VI, Iurov IB, Giovanucci-Uzielli ML, Demidova IA, Gianti L, Villard L, Iurov II, Beresheva AK, Novikov PV: Genotype-phenotype correlations in Rett syndrome: the study of Russian cohort of patients. Zh Nevrol Psikhiatr Im S S Korsakova 2002, 102(10):23–29.PubMed
- Iurov II, Vorsanova SG, Voinova-Ulas VI, Villard L, Demidova IA, Giunti L, Guivabyccu-Uzielli ML, Budilov AV, Beresheva AK, Novikov PV, Iurov IB: Epigenetic study of Rett’s syndrome as an adequate model for autistic disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2005, 105(7):4–11.PubMed
- Trevathan E, Moser H, Rett Syndrome Diagnostic Criteria Work Group: Diagnostic criteria for Rett syndrome. The rett syndrome diagnostic criteria work group. Ann Neurol 1988, 23: 425–428.View Article
- Temudo T, Santos M, Ramos E, Dias K, Vieira JP, Moreira A, Calado E, Carrilho I, Oliveira G, Levy A, Barbot C, Fonseca M, Cabral A, Cabral P, Monteiro J, Borges L, Gomes R, Mira G, Pereira SA, Santos M, Fernandes A, Epplen JT, Sequeiros J, Maciel P: Rett syndrome with and without detected MECP2 mutations: an attempt to redefine phenotypes. Brain Dev 2011, 33: 69–76. 10.1016/j.braindev.2010.01.004View ArticlePubMed
- Iourov IY, Vorsanova SG, Yurov YB: Molecular cytogenetics and cytogenomics of brain diseases. Curr Genomics 2008, 9: 452–465. 10.2174/138920208786241216PubMed CentralView ArticlePubMed
- Mencarelli MA, Kleefstra T, Katzaki E, Papa FT, Cohen M, Pfundt R, Ariani F, Meloni I, Mari F, Renieri A: 14q12 Microdeletion syndrome and congenital variant of Rett syndrome. Eur J Med Genet 2009, 52: 148–152. 10.1016/j.ejmg.2009.03.004View ArticlePubMed
- Bourdon V, Philippe C, Labrune O, Amsallem D, Arnould C, Jonveaux P: A detailed analysis of the MECP2 gene: prevalence of recurrent mutations and gross DNA rearrangements in Rett syndrome patients. Hum Genet 2001, 108: 43–50. 10.1007/s004390000422View ArticlePubMed
- Ravn K, Nielsen JB, Skjeldal OH, Kerr A, Hulten M, Schwartz M: Large genomic rearrangements in MECP2. Hum Mutat 2005, 25: 324.View ArticlePubMed
- Archer HL, Whatley SD, Evans JC, Ravine D, Huppke P, Kerr A, Bunyan D, Kerr B, Sweeney E, Davies SJ, Reardon W, Horn J, MacDermot KD, Smith RA, Magee A, Donaldson A, Crow Y, Hermon G, Miedzybrodzka Z, Cooper DN, Lazarou L, Butler R, Sampson J, Pilz DT, Laccone F, Clarke AJ: Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. J Med Genet 2006, 43: 451–456.PubMed CentralView ArticlePubMed
- Bebbington A, Downs J, Percy A, Pineda M, Zeev BB, Bahi-Buisson N, Leonard H: The phenotype associated with a large deletion on MECP2. Eur J Hum Genet 2012, 20: 921–927. 10.1038/ejhg.2012.34PubMed CentralView ArticlePubMed
- Kobayashi Y, Ohashi T, Akasaka N, Tohyama J: Congenital variant of Rett syndrome due to an intragenic large deletion in MECP2. Brain Dev 2012, 34: 601–604. 10.1016/j.braindev.2011.09.014View ArticlePubMed
- Chen RZ, Akbarian S, Tudor M, Jaenisch R: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001, 27: 327–331. 10.1038/85906View ArticlePubMed
- Guy J, Hendrich B, Holmes M, Martin JE, Bird A: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001, 27: 322–326. 10.1038/85899View ArticlePubMed
- Agarwal N, Becker A, Jost KL, Haase S, Thakur BK, Brero A, Hardt T, Kudo S, Leonhardt H, Cardoso MC: MeCP2 Rett mutations affect large scale chromatin organization. Hum Mol Genet 2011, 20: 4187–4195. 10.1093/hmg/ddr346View ArticlePubMed
- Singleton MK, Gonzales ML, Leung KN, Yasui DH, Schroeder DI, Dunaway K, LaSalle JM: MeCP2 is required for global heterochromatic and nucleolar changes during activity-dependent neuronal maturation. Neurobiol Dis 2011, 43: 190–200. 10.1016/j.nbd.2011.03.011PubMed CentralView ArticlePubMed
- Guy J, Cheval H, Selfridge J, Bird A: The role of MeCP2 in the brain. Annu Rev Cell Dev Biol 2011, 27: 631–652. 10.1146/annurev-cellbio-092910-154121View ArticlePubMed
- Iourov IY, Vorsanova SG, Yurov YB: Chromosomal mosaicism goes global. Mol Cytogenet 2008, 1: 26. 10.1186/1755-8166-1-26PubMed CentralView ArticlePubMed
- Iourov IY, Vorsanova SG, Yurov YB: Somatic genome variations in health and disease. Curr Genomics 2010, 11: 387–396. 10.2174/138920210793176065PubMed CentralView ArticlePubMed
- Iourov IY, Vorsanova SG, Yurov YB: Chromosomal variation in mammalian neuronal cells: known facts and attractive hypotheses. Int Rev Cytol 2006, 249: 143–191.View ArticlePubMed
- Vorsanova SG, Yurov IY, Demidova IA, Voinova-Ulas VY, Kravets VS, Solov’ev IV, Gorbachevskaya NL, Yurov YB: Variability in the heterochromatin regions of the chromosomes and chromosomal anomalies in children with autism: identification of genetic markers of autistic spectrum disorders. Neurosci Behav Physiol 2007, 37: 553–558. 10.1007/s11055-007-0052-1View ArticlePubMed
- Vorsanova SG, Voinova VY, Yurov IY, Kurinnaya OS, Demidova IA, Yurov YB: Cytogenetic, molecular-cytogenetic, and clinical-genealogical studies of the mothers of children with autism: a search for familial genetic markers for autistic disorders. Neurosci Behav Physiol 2010, 40: 745–756. 10.1007/s11055-010-9321-5View ArticlePubMed
- Yurov YB, Vorsanova SG, Iourov IY, Demidova IA, Beresheva AK, Kravetz VS, Monakhov VV, Kolotii AD, Voinova-Ulas VY, Gorbachevskaya NL: Unexplained autism is frequently associated with low-level mosaic aneuploidy. J Med Genet 2007, 44: 521–525. 10.1136/jmg.2007.049312PubMed CentralView ArticlePubMed
- Abrahams BS, Geschwind DH: Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 2008, 9: 341–355. 10.1038/nrg2346PubMed CentralView ArticlePubMed
- Neul JL: The relationship of Rett syndrome and MECP2 disorders to autism. Dialogues Clin Neurosci 2012, 14: 253–262.PubMed CentralPubMed
- Shaffer LG, Bejjani BA, Torchia B, Kirkpatrick S, Coppinger J, Ballif BC: The identification of microdeletion syndromes and other chromosome abnormalities:cytogenetic methods of the past, new technologies for the future. Am J Med Genet C Semin Med Genet 2007, 145C: 335–345. 10.1002/ajmg.c.30152View ArticlePubMed
- Vorsanova SG, Yurov YB, Iourov IY: Human interphase chromosomes: a review of available molecular cytogenetic technologies. Mol Cytogenet 2010, 3: 1. 10.1186/1755-8166-3-1PubMed CentralView ArticlePubMed
- Iourov IY, Vorsanova SG, Yurov YB: Single cell genomics of the brain: focus on neuronal diversity and neuropsychiatric diseases. Curr Genomics 2012, 13: 477–488. 10.2174/138920212802510439PubMed CentralView ArticlePubMed
- Bauters M, Van Esch H, Friez MJ, Boespflug-Tanguy O, Zenker M, Vianna-Morgante AM, Rosenberg C, Ignatius J, Raynaud M, Hollanders K, Govaerts K, Vandenreijt K, Niel F, Blanc P, Stevenson RE, Fryns JP, Marynen P, Schwartz CE, Froyen G: Nonrecurrent MECP2 duplications mediated by genomic architecture-driven DNA breaks and break-induced replication repair. Genome Res 2008, 18: 847–858. 10.1101/gr.075903.107PubMed CentralView ArticlePubMed
- El-Hattab AW, Fang P, Jin W, Hughes JR, Gibson JB, Patel GS, Grange DK, Manwaring LP, Patel A, Stankiewicz P, Cheung SW: Int22h-1/int22h-2-mediated Xq28 rearrangements: intellectual disability associated with duplications and in utero male lethality with deletions. J Med Genet 2011, 48: 840–850. 10.1136/jmedgenet-2011-100125View ArticlePubMed
- Vorsanova SG, Demidova IA, Ulas VY, Soloviev IV, Kazantzeva LZ, Yurov YB: Cytogenetic and molecular-cytogenetic investigation of Rett syndrome: analysis of 31 cases. Neuroreport 1996, 8: 187–189. 10.1097/00001756-199612200-00038View ArticlePubMed
- Hochstenbach R, Buizer-Voskamp JE, Vorstman JA, Ophoff RA: Genome arrays for the detection of copy number variations in idiopathic mental retardation, idiopathic generalized epilepsy and neuropsychiatric disorders: lessons for diagnostic workflow and research. Cytogenet Genome Res 2011, 135: 174–202. 10.1159/000332928View ArticlePubMed
- Iourov IY, Vorsanova SG, Yurov YB: Somatic cell genomics of brain disorders: a new opportunity to clarify genetic-environmental interactions. Cytogenet Genome Res 2013, 139: 181–188. 10.1159/000347053View ArticlePubMed
- Giunti L, Pelagatti S, Lazzerini V, Guarducci S, Lapi E, Coviello S, Cecconi A, Ombroni L, Andreucci E, Sani I, Brusaferri A, Lasagni A, Ricotti G, Giometto B, Nicolao P, Gasparini P, Granatiero M, Uzielli ML: Spectrum and distribution of MECP2 mutations in 64 Italian Rett syndrome girls: tentative genotype/phenotype correlation. Brain Dev 2001, 23(Suppl 1):S242-S245.View ArticlePubMed
- Vorsanova SG, Iurov II, Kurinnaia OS, Voinova VI, Iurov IB: Genomic abnormalities in children with mental retardation and autism: the use of comparative genomic hybridization in situ (HRCGH) and molecular karyotyping with DNA-microchips (array CGH). Zh Nevrol Psikhiatr Im S S Korsakova 2013, 113(8):46–49.PubMed
- Duker AL, Ballif BC, Bawle EV, Person RE, Mahadevan S, Alliman S, Thompson R, Traylor R, Bejjani BA, Shaffer LG, Rosenfeld JA, Lamb AN, Sahoo T: Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. Eur J Hum Genet 2010, 18: 1196–1201. 10.1038/ejhg.2010.102PubMed CentralView ArticlePubMed
- Vorsanova SG, Yurov YB, Kolotii AD, Soloviev IV: FISH analysis of replication and transcription of chromosome X loci: new approach for genetic analysis of Rett syndrome. Brain Dev 2001, 23(Suppl 1):S191-S195.View ArticlePubMed
- D’Esposito M, Quaderi NA, Ciccodicola A, Bruni P, Esposito T, D’Urso M, Brown SD: Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mamm Genome 1996, 7: 533–535. 10.1007/s003359900157View ArticlePubMed
- Griswold AJ, Ma D, Cukier HN, Nations LD, Schmidt MA, Chung RH, Jaworski JM, Salyakina D, Konidari I, Whitehead PL, Wright HH, Abramson RK, Williams SM, Menon R, Martin ER, Haines JL, Gilbert JR, Cuccaro ML, Pericak-Vance MA: Evaluation of copy number variations reveals novel candidate genes in autism spectrum disorder-associated pathways. Hum Mol Genet 2012, 21: 3513–3523. 10.1093/hmg/dds164PubMed CentralView ArticlePubMed
- Rio M, Royer G, Gobin S, de Blois MC, Ozilou C, Bernheim A, Nizon M, Munnich A, Bonnefont JP, Romana S, Vekemans M, Turleau C, Malan V: Monozygotic twins discordant for submicroscopic chromosomal anomalies in 2p25.3 region detected by array CGH. Clin Genet 2013, 84: 31–36. 10.1111/cge.12036View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.